Our Officers & Committees
2022-2024 Presidency
ISH Council
The Council is responsible for furthering the aspirations and activities of the ISH, ensuring its efficient running and controlling its property and funds. ISH Council members are also Trustees of the Charity.
The Executive of the Council (Executive Committee) takes a critical role in helping the Council set policies and goals for the Society, and is delegated to act for the Council in the day-to-day activities of the Society, such as providing direction to the ISH Secretariat, of making the necessary arrangements for the next ISH Biennial Scientific and General Meetings and other scientific activities, of overseeing the work of all committees and working parties, and for giving final consideration for all nominations for membership.
Executive Committee
Council Members
Bryan Williams
My research currently focuses on clinical studies and physiological aspects of resistant and complex hypertension. I have also had comprehensive experience in leading the development of hypertension guidelines.
Hiroshi Itoh
George Stergiou
Research work focused on blood pressure measurement methodology and technology; Diagnostic methods and protocols for hypertension evaluation; Development and evaluation of novel medical technology for blood pressure measurement; Development of validations standards for blood pressure measuring devices; Hypertension diagnosis in children and adolescents.
Fadi Charchar
My research interests focus on genomics of cardiovascular disease in humans and animal models. I have a special interest in the contribution of the Y chromosome and microRNA to hypertension.
Nadia Khan
I am a clinician scientist in epidemiology and health services research. My research area is focused on ethnic and sex differences in hypertension and cardiovascular disease chronic disease management.
Maciej Tomaszewski
My research interests focus primarily on genetics and genomics of cardiovascular disorders with a particular emphasis on essential hypertension and its complications.
I am also interested in genetic and environmental background of sexual dimorphism in cardiovascular risk (why men develop and die of cardiovascular disorders more frequently than age-matched women).
Council Members / Co-opted Council Attendees
Claudio Borghi
My main areas of interest are the hypertension and related cardiovascular risk factors and drug therapy of hypertensive disease. In particular I am very interested in the interactions between hypertensive disease and metabolic risk factors paying a special attention to epidemiology, pathophysiology and drug treatment including the options supporting the use of different preventive approaches in patients with complex CV risk profile. I am also involved in the development of a nutraceutical approach to the management of hypertension and related risk factors.
Dylan Burger
My research focuses on the cellular mechanisms of oxidative stress, inflammation and vascular dysfunction in hypertension. I have a particular interest in the role of microparticles, tiny cellular fragments shed from stressed cells of the vasculature, in hypertension and vascular disease.
Rafael Castillo
As a senior clinical cardiologist at the Manila Doctor’s Hospital and a pioneering faculty member at the Adventist University College of Medicine, I’m part of a group involved in clinical trials evaluating drug and non-drug interventions in the management of high-risk hypertensive patients with various comorbidities. I’m a past president of the Asian Pacific Society of Hypertension, Philippine Heart Association/Philippine College of Cardiology, Philippine Society of Hypertension; and past chair of the Philippine Specialty Board of Adult Cardiology.
Myeong-Chan Cho
As a clinician scientist, I have conducted many translational research projects and my research interest is molecular and genetic mechanisms of hypertension, cardiac hypertrophy and failure. I have conducted the GWAS project to evaluate the genetic influence on blood pressure in Asian people. Several novel gene loci were revealed. Recent research directions include cohort studies and precision medicine for the treatment and prevention of hypertension.
I am currently working as a principal investigator of a Korean government-sponsored cohort study of elderly hypertensive patients, which will provide important insights into the clinical characteristics, prognosis and blood pressure targets in the elderly hypertensive population of Korea. In collaboration with colleagues in other Asian countries, I would like to conduct basic science and translational clinical research in order to identify novel treatment targets and generate Asian Hypertension Guidelines.
Tazeen Jafar
My research interests lie in the protective arm of the renin angiotensin system, in particular the angiotensin AT2-receptor and the receptor MAS, spanning from the basic biology of these receptors over pre-clinical studies to test their therapeutic efficacy in cardiovascular (e.g. heart failure, hypertensive and diabetic end organ damage, stroke) and other diseases to the involvement in the development of AT2-recepor agonists for future clinical use.
Kazuomi Kario
My research interests lie in the protective arm of the renin angiotensin system, in particular the angiotensin AT2-receptor and the receptor MAS, spanning from the basic biology of these receptors over pre-clinical studies to test their therapeutic efficacy in cardiovascular (e.g. heart failure, hypertensive and diabetic end organ damage, stroke) and other diseases to the involvement in the development of AT2-recepor agonists for future clinical use.
Dorairaj Prabhakaran
I am a cardiologist and epidemiologist and currently the Executive Director of Initiative for Cardiovascular Health in Developing Countries (ICHEALTH) and Director Centre of Excellence, Centre for Cardio-metabolic Risk Reduction in South Asia (strategic grant funded by the National Institutes of Health and United Health group) at the Public Health Foundation of India.
Cesar Romero
My research interests lie in the protective arm of the renin angiotensin system, in particular the angiotensin AT2-receptor and the receptor MAS, spanning from the basic biology of these receptors over pre-clinical studies to test their therapeutic efficacy in cardiovascular (e.g. heart failure, hypertensive and diabetic end organ damage, stroke) and other diseases to the involvement in the development of AT2-recepor agonists for future clinical use.
Ulrike (Muscha) Steckelings
My research interests lie in the protective arm of the renin angiotensin system, in particular the angiotensin AT2-receptor and the receptor MAS, spanning from the basic biology of these receptors over pre-clinical studies to test their therapeutic efficacy in cardiovascular (e.g. heart failure, hypertensive and diabetic end organ damage, stroke) and other diseases to the involvement in the development of AT2-recepor agonists for future clinical use.
Augustine Odili
My research interests lie in the protective arm of the renin angiotensin system, in particular the angiotensin AT2-receptor and the receptor MAS, spanning from the basic biology of these receptors over pre-clinical studies to test their therapeutic efficacy in cardiovascular (e.g. heart failure, hypertensive and diabetic end organ damage, stroke) and other diseases to the involvement in the development of AT2-recepor agonists for future clinical use.
Committees
Working groups and Taskforces
The ISH President, Executive Committee and membership of Council changed at the ISH General Meeting in Kyoto, Japan on 15th October 2022.
Membership of the following committees and groups will be updated shortly for the 2022-2024 presidency.
Awards
Committee
George Stergiou
Communications
Committee
Anastasia Mihailidou
Corporate Liaison
Committee
Bryan Williams
ESH-ISH Journal of Hypertension
Committee
Maciej Tomaszewski
Finance
Committee
Fadi Charchar
Mentorship and Training
Committee
Augusto Montezano
Membership
Committee
Debora Simoes de Almeida Colombari
New Investigator
Committee
Dean Picone
Research and Education
Committee
Nadia Khan
Claudio Borghi
Women in Hypertension
Committee
Niamh Chapman
Lizzy Brewster
Mansi Patil
Ching Siew-Mooi
ISH Regional Advisory Groups
RAGs
Africa
Regional Advisory Group (RAG)
Augustine Odili
Countries included: Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic, Chad, Comoros, Congo, Cote d’Ivoire, Democratic Republic of Congo, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Togo, Uganda, United Republic of Tanzania, Zambia, Zimbabwe
Americas
Regional Advisory Group (RAG)
Cesar Romero
Countries included: Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominical Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, USA, Uruguay, Venezuela
Asia Pacific (APAC)
Regional Advisory Group (RAG)
Wook Bum Pyun
Countries included: Australia, Brunei Darussalam, Cambodia, China, Cook Islands, Democratic People’s Republic of Korea (North Korea), East Timor, Fiji, Indonesia, Japan, Kiribati, Laos, Malaysia, Marshall Islands, Micronesia, Mongolia, Myanmar, Nauru, Niue, New Zealand, Palau, Papua New Guinea, Philippines, Republic of Korea (South Korea), Samoa, Singapore, Taiwan, Thailand, Taiwan, Vietnam
Europe
Regional Advisory Group (RAG)
Claudio Borghi
Countries included: Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Malta, Monaco, Montenegro, Netherlands, North Macedonia, Norway, Poland, Portugal, Republic of Moldova, Romania, Russian Federation, San Merino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, UK
Middle East and North Africa (MENA)
Regional Advisory Group (RAG)
Jafar Alsaid
Countries included: Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, Syria, Syrian Arab Republic, Tunisia, United Arab Emirates, Yemen
South and Central Asia (SACA)
Regional Advisory Group (RAG)
Dorairaj Prabhakaran
Countries included: Afghanistan, Bangladesh, Bhutan, India, Kazakhstan, Kyrgyzstan, Maldives, Nepal, Pakistan, Sri Lanka, Tajikistan, Turkmenistan, Uzbekistan
Taskforces and Special Projects
Focus Group
Innovations in Blood Pressure Measurement
Kazuomi Kario
ISH Academy
Erika Jones
Public Material
Taskforce
Anastasia Mihailidou
Dylan Burger
Evi Christofidou
Abhinav Gupta
Krasimira Hristova
Erika Jones
Nadia Khan
I am a clinician scientist in epidemiology and health services research. My research area is focused on ethnic and sex differences in hypertension and cardiovascular disease chronic disease management.
Vikas Kapil
Alice-Veronika Lamwaka
Tiny Masupe
Quynh Nhu Dinh
;
